Anticancer Bioscience is developing a first-in-class oncology platform built on mechanistic rigor and clinical executability. Programs progress from discovery into early clinical development under clear translational criteria, with the aim of building assets ready for global development.
The company is well capitalized and operates with strategic independence. We engage selectively with life science investors and pharmaceutical partners who add scientific judgment, development experience, and long-term alignment—and who value execution quality over visibility.
See our latest financing update.
For strategic investment or partnership discussions, please contact us.
